Shulman L P
Department of Obstetrics and Gynecology, Division of Reproductive Genetics, University of Illinois at Chicago, Chicago, Illinois 60612-7313, USA.
J Womens Health Gend Based Med. 2000 Sep;9(7):725-9. doi: 10.1089/15246090050147637.
Contraceptive choices for women in the United States will soon expand with the expected Food and Drug Administration (FDA) approval (in early summer 2000) of a once-a-month injectable combination contraceptive. Containing 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate (MPA/E2C) (Lunelletrade mark/Lunellatrade mark, Pharmacia and Upjohn, Peapack, NJ), this monthly injectable method combines the convenience and contraceptive efficacy of longacting steroid methods with the cycle control, return to fertility, and side effect profile more typical of combination low-dose oral contraceptives. The introduction of this novel contraceptive will expand the number of safe, convenient, and effective contraceptives, and it may be used and accepted by women who are not or have not been inclined to use an available reversible contraceptive method in a correct and consistent manner.
随着美国食品药品监督管理局（FDA）预计在2000年夏初批准一种每月注射一次的复方避孕药，美国女性的避孕选择将很快增加。这种每月注射一次的方法含有25毫克醋酸甲羟孕酮和5毫克环丙孕酮雌二醇（MPA/E2C）（商品名Lunelle/Lunella，法玛西亚普强公司，皮帕克，新泽西州），它将长效甾体避孕方法的便利性和避孕效果与复方低剂量口服避孕药更典型的周期控制、恢复生育能力及副作用特征结合在一起。这种新型避孕药的推出将增加安全、方便且有效的避孕方法的种类，那些未曾或一直不愿意正确且持续使用现有可逆避孕方法的女性也可能会使用并接受它。
